| 1 |
28937990 | Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. | 2017 |
1 |
| 2 |
22579611 | Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. | 2012 Sep 25 |
3 |
| 3 |
20549197 | Bisphosphonate inhibits bone turnover in OPG(-/-) mice via a depressive effect on both osteoclasts and osteoblasts. | 2010 Aug |
4 |
| 4 |
18715136 | Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin. | 2009 Jan |
1 |
| 5 |
19432105 | [Osteoclastogenesis and bone resorption]. | 2009 May |
1 |
| 6 |
18183447 | Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. | 2008 Feb |
10 |
| 7 |
18404739 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. | 2008 Oct |
1 |
| 8 |
15845617 | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | 2005 Aug |
1 |
| 9 |
16193235 | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 Oct |
1 |
| 10 |
12548581 | Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | 2003 Feb 1 |
1 |